Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Level II - Ask's thinning....
I tend to believe it's NOT FAKE. $33,000 vs. $10,800,000
That's $10.8 Million worth. Ummmmm..... okay? Thanks!
Seriously?? It seems exaggerated. When did it happen and at what price?
"I cannot handle a person that recruiters bring into us. So they can be a corporate person sitting in their office and wanting to hire and entire staff and not work. You need to be a worker be at Elite, that's what we all are".--- Nasrat
scroll down.... click on "See More Posts on ELTP Message Board"
What seems to be the problem?
"On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”). The sale has been consummated."
"Elite executed a Manufacturing and Supply agreement on November 21, 2022, with Pyros in conjunction with the sale. Under the terms of the commercial Manufacturing and Supply Agreement, Elite will be compensated at an agreed-upon price for the manufacturing and packaging of the Product for commercial sale for a term of three years."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222033823/form8-k.htm
Wowwwza!!! Super-Duper news! Thanks for the update.
It's Happening !!! SEC Charges Investment Adviser and Principal in Abusive Naked Short Selling Scheme
FOR IMMEDIATE RELEASE
Washington D.C., June 12, 2023 —
The Securities and Exchange Commission today charged investment adviser Sabby Management LLC and its managing partner, Hal D. Mintz, with fraud in connection with a long running scheme involving misrepresentations and violations of rules for short selling and order making, as well as other violative trading, that generated more than $2 million in illegal profits.
The SEC’s complaint alleges that, from at least March 2017 through May 2019, Sabby and Mintz repeatedly circumvented trading rules to conduct unlawful trades in the stock of at least 10 public companies. Short selling is a legal practice where, generally, a trader borrows a security from a securityholder and sells the security at one price, speculating that the trader can buy the security at a lower price in the future before it must be returned to its owner. As alleged in the complaint, for example, Sabby and Mintz engaged in illegal “naked short selling” by intentionally and improperly placing short sales when they knew or were reckless in not knowing that they had not borrowed or located the shares, and then failed to make timely delivery of the shares. According to the SEC’s complaint, the purpose of Sabby and Mintz’s fraudulent scheme was to earn profits they could not have gained through legal trading.
Additionally, as the complaint alleges, on occasion Sabby and Mintz used their naked short selling to artificially deflate the price of securities, allowing them to obtain more shares at a cheaper price.
The SEC’s complaint further alleges that Sabby and Mintz tried to conceal their fraudulent trading, including by using securities acquired after the trades to make it appear to brokers executing the trades that they had complied with the requirement to have borrowed or located the shares prior to their trades. As the complaint alleges, when questioned by at least one broker regarding their trading, Sabby and Mintz repeatedly lied about the trading.
“The SEC alleges that Sabby and Mintz attempted to game the system and make an illegal profit,” said Carolyn Welshhans, Associate Director of the SEC’s Division of Enforcement. “When someone uses naked shorts or other manipulative practices to cheat the market and investors, the SEC will ensure that they are held accountable.”
The SEC’s complaint, filed in the U.S. District Court for the District of New Jersey, charges Sabby and Mintz with violations of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b-21 thereunder. The complaint also charges Sabby with violations of Sections 204 and 206(4) of the Investment Advisers Act of 1940 and Rules 204-2 and 206(4)-7 thereunder and charges Mintz with aiding and abetting those violations. The complaint seeks permanent injunctive relief, disgorgement of ill-gotten gains plus prejudgment interest, and civil penalties.
https://www.sec.gov/news/press-release/2023-107
Just being realistic here. Its not really hard to understand the filing.
Clear and Simple actions leading to massive dilution greatly for the benefit of DIP Ltd.
From SEC Form 8-K
"In addition, the Amendment included an adjustment to the exercise price of the 621,470,562 Warrants issued and sold to the Seller on April 16, 2021, from $0.021 per share to a nominal price per share, which the board of directors of the Company (the “Board”) subsequently determined to be $0.001 per share. Each of the Warrants continues to be exercisable until April 16, 2031".
"On March 6, 2023, the holders of a majority of the issued and outstanding stock of the Company approved an increase in the Company’s authorized capital from 3,500,000,000 shares of common stock, par value $0.001 per share, to 5,000,000,000 shares of common stock, par value $0.001 per share (the “Authorized Capital Increase”). On May 5, 2023, the Company formally completed the Authorized Capital Increase by filing a Certificate of Amendment with the Nevada Secretary of State, a copy of which is attached hereto as Exhibit 3.6".
Item 8.01 Other Events
On April 24, 2023, the Board approved an amendment to the exercise price of an aggregate of 410,000,000 previously-issued Warrants (collectively, the “2022 Warrants”) and an aggregate of 152,000,000 previously-issued stock options (collectively, the “Options”, and together with the 2022 Warrants, the “Issued Securities”) from $0.025 to $0.005 per share, and concurrently adopted an Option and Warrant Exercise Process and Share Sales Policy (the “Policy”),
This is why the increased of Authorized Shares from 3.5 Billion to 5 Billion common shares.
Not good :(
On April 23, 2023, VoIP-Pal.com Inc. (the “Company”), Digifonica Intellectual Properties (DIP) Limited (the “Seller”) and Digifonica (International) Limited entered into an amendment (the “Amendment”) to the share transfer agreement between the parties originally dated June 25, 2013, and subsequently amended on July 18, 2013, October 6, 2013, October 31, 2013, November 25, 2013, March 17, 2014 and April 21, 2021 (collectively, the “STA”). Pursuant to the Amendment, the parties agreed to delete Section 5.5 of the STA, which required the Company to issue to the Seller or the Seller’s assignee warrants to purchase shares of the Company’s common stock (each. a “Warrant”) in a sufficient quantity such that when exercised, the shares of common stock issuable upon the exercise of the Warrants plus certain previously-issued shares of common stock held by the Seller, would equal 40% of the Company’s outstanding share capital,and replace it with substantially similar language plus a requirement for the Company to issue to the Seller that number of shares of the Series A preferred stock of the Company that would allow the Seller to retain voting rights equivalent to the same 40% interest.
In addition, the Amendment included an adjustment to the exercise price of the 621,470,562 Warrants issued and sold to the Seller on April 16, 2021, from $0.021 per share to a nominal price per share, which the board of directors of the Company (the “Board”) subsequently determined to be $0.001 per share. Each of the Warrants continues to be exercisable until April 16, 2031.
On March 6, 2023, the holders of a majority of the issued and outstanding stock of the Company approved an increase in the Company’s authorized capital from 3,500,000,000 shares of common stock, par value $0.001 per share, to 5,000,000,000 shares of common stock, par value $0.001 per share (the “Authorized Capital Increase”). On May 5, 2023, the Company formally completed the Authorized Capital Increase by filing a Certificate of Amendment with the Nevada Secretary of State, a copy of which is attached hereto as Exhibit 3.6.
Item 8.01 Other Events
On April 24, 2023, the Board approved an amendment to the exercise price of an aggregate of 410,000,000 previously-issued Warrants (collectively, the “2022 Warrants”) and an aggregate of 152,000,000 previously-issued stock options (collectively, the “Options”, and together with the 2022 Warrants, the “Issued Securities”) from $0.025 to $0.005 per share, and concurrently adopted an Option and Warrant Exercise Process and Share Sales Policy (the “Policy”),
Continuation of Accumulation from last week still in force. NICE!!!
Yes, with its subsidiary Accord Healthcare. Intas through Accord Healthcare recently acquired the generics business of Actavis in UK and Ireland.
Accord Healthcare has been operating in the US since 2009. Headquartered near Research Triangle in Durham, North Carolina, Accord Healthcare is the US subsidiary of Intas Pharmaceuticals with US annual sales of $668M*. Accord Healthcare’s US leadership team oversees development, clinical research, manufacturing, regulatory, and commercial activities related to its products.
https://www.accordhealthcare.us/our-team/
Intas Pharmaceuticals Ltd. (“Intas”), through its wholly owned subsidiary Accord Healthcare
Ltd. (“Accord”), announced today that it has entered into definitive agreements to acquire
Actavis UK Ltd. & Actavis Ireland Ltd. (“Actavis UK & Ireland”) from Teva Pharmaceutical
Industries Ltd. (“Teva”) for an enterprise value of approximately £600 million payable in
cash. The transaction is part of the European Commission’s anti-trust divestiture
requirements arising from Teva’s acquisition of Actavis Generics.
I wonder if they're looking to acquire/expand a generic business in the US as well.
Likewise and thanks!
Great! Can't resist at this ridiculously low sp. Will be doing the same.
Someone's got a good appetite of buying a good block today. Nice!:)
Netlist, Inc (NLST) the Victor vs. Samsung...$300+Million (Plus treble 2x...3x...? for WILLFUL IP INFRINGEMENT)
https://www.reuters.com/legal/samsung-hit-with-303-mln-jury-verdict-computer-memory-patent-lawsuit-2023-04-21/
Video:
Netlist, Inc (NLST) the Victor vs. Samsung...$300+Million (Plus treble 2x...3x...? for WILLFUL IP INFRINGEMENT)
https://www.reuters.com/legal/samsung-hit-with-303-mln-jury-verdict-computer-memory-patent-lawsuit-2023-04-21/
Video:
Oh wait! Where did Mr. Kirkov previously worked again? Hmmmmm....
Could cause a ripple effect.
Effects of Phase 6 kicking in??? Looking at SVB Financial Group (SIVB) is a total mess!
Tampering? They'll get caught in an instant!
$10,795,000 my prediction
How can we expect counterfeit shares (short/naked shorted) be reported? That explains the recorded discrepancy. No?
Gonna take the risk this time following FDA guidelines should do the trick.
It's happening. Especially to ELTP for years!
If approved, will this change course the approval process of abuse deterrent (opioid) pain meds?
U.S. FDA panel to review Emergent's OTC opioid overdose drug
Jan 10 (Reuters) - The U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc's over-the-counter (OTC) nasal spray to treat suspected opioid overdoses.
Emergent is seeking the Food and Drug Administration's (FDA)approval for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country.
Last month, the health agency accorded Narcan's marketing application a priority review status, and is set to make its decision by March 29. The panel will assess the adequacy of data that supports the nonprescription use of the drug.
The country's worsening opioid crisis has prompted the Biden administration to develop newer strategies, including the use of naloxone, a medication that can reverse opioid overdoses.
Late last year, the agency had said naloxone might be safe and effective for over-the-counter use in some forms, potentially paving the way for its use federally and encouraging more manufacturers to seek approval for prescription-free use.
Government estimates peg drug-related overdose deaths in the United States at more than 100,000 during 2021, a near 15% increase from the year earlier. (Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)
https://finance.yahoo.com/news/u-fda-panel-review-emergents-203655444.html
So... Why waste your time here?
Now Elon Musk is weighing in on Adderall issue. He's not a fan though :( Maybe he needs it? LOL
https://www.thestreet.com/lifestyle/health/elon-musk-warns-against-popular-stimulant-adderall?puc=yahoo&cm_ven=YAHOO
Awesome!!! Very much appreciated, Sir!
Excited although a bit confused as to where you got this from the cc transcript. I don't recall such statement maybe I missed it? Kindly copy&paste it? TIA
Dopamine agonists can be used to treat various conditions, such as:
* Parkinson’s disease
* restless leg syndrome
* neuroleptic malignant syndrome, a rare side effect of antipsychotic medication
* hyperprolactinemia, a condition that occurs when a person has too high levels of the hormone prolactin
* type 2 diabetes
* hypertensive emergencies, which occur when a person has severely high blood pressure and organ damage
Yeah! Noticed that too. Interesting!
WRONG!
Excerpt from the latest CC (November 15, 2022 11:30 AM ET) (rrr2003 post #375653)
CEO NH --We have never withdrawn SequestOx. It’s still a pending application with the FDA. We just did not finish all of the clinical trials they ask us to do. That’ll cost tons of money, millions of dollars, but we cannot resubmit what has not been withdrawn. It’s still an active application. We have decided not to pursue it because of financials as I’ve explained many times before.
Looks like there is activity with SequestOx on 12/17/2022. Any comment ???
Came across this: SequestOx. Thoughts?
Dates
Modify
2022-12-17
Create
2015-02-21
https://pubchem.ncbi.nlm.nih.gov/compound/SequestOx
That is why we have a gov agency called "SEC". You got issues? REPORT IT!
Good one!!! :D
Orbimed Advisors, LLC and Directors liquidated all their common shares. Form 4 filed Nov. 25, 2022.
Click on Ownership Disclosures -- https://www.sec.gov/edgar/browse/?CIK=1595585&owner=exclude
>>> Move on to ELTP before a monster run.